Septerna (NASDAQ:SEPN) Trading 7.7% Higher - Should You Buy?

Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price was up 7.7% on Friday . The company traded as high as $23.09 and last traded at $23.00. Approximately 38,381 shares were traded during trading, a decline of 65% from the average daily volume of 109,190 shares. The stock had previously closed at $21.35.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. TD Cowen initiated coverage on shares of Septerna in a report on Tuesday, November 19th. They set a "buy" rating on the stock. Cantor Fitzgerald began coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued an "overweight" rating and a $50.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price objective for the company. Finally, Wells Fargo & Company started coverage on Septerna in a research report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 target price on the stock.

Septerna Trading Up 11.0 %

The stock has a 50 day moving average of $23.70.

Insider Buying and Selling

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the company's stock in a transaction that occurred on Monday, October 28th. The stock was purchased at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the acquisition, the insider now owns 6,215,591 shares of the company's stock, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.